» Articles » PMID: 16081770

Cutting Edge: Chemoattractant Receptor-homologous Molecule Expressed on Th2 Cells Plays a Restricting Role on IL-5 Production and Eosinophil Recruitment

Overview
Journal J Immunol
Date 2005 Aug 6
PMID 16081770
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

PGs play key regulatory roles in inflammation and immunity. PGD2, released from mast cells and Th2 cells during allergic responses, has recently been shown to target a novel receptor, chemoattractant receptor-homologous molecule expressed TH2 cells (CRTH2), in addition to the classic PGD (DP) receptor. CRTH2 is expressed on Th2 cells and eosinophils and mediates chemotaxis of these cells to PGD2. Thus, CRTH2 is thought to be a key receptor mediating eosinophil and Th2 cell recruitment during allergic responses. To examine the role of CRTH2 in this context in vivo, we generated CRTH2 knockout mice. Surprisingly, in an allergic inflammatory model of asthma, CRTH2 knockout mice showed enhanced eosinophil recruitment into the lung compared with wild-type littermate mice. This is consistent with our observation that CRTH2 knockout cells produce significantly higher amounts of IL-5 and IL-3 in vitro. These results suggest a nonredundant role of CRTH2 in restricting eosinophilia and allergic response in vivo.

Citing Articles

Endogenous PGD2 acting on DP2 receptor counter regulates Schistosoma mansoni infection-driven hepatic granulomatous fibrosis.

Pezzella-Ferreira G, Pao C, Bellas I, Luna-Gomes T, Muniz V, Paiva L PLoS Pathog. 2024; 20(8):e1011812.

PMID: 39173086 PMC: 11386465. DOI: 10.1371/journal.ppat.1011812.


Crth2 receptor signaling down-regulates lipopolysaccharide-induced NF-κB activation in murine macrophages changes in intracellular calcium.

Diwakar B, Yoast R, Nettleford S, Qian F, Lee T, Berry S FASEB J. 2019; 33(11):12838-12852.

PMID: 31518163 PMC: 6988853. DOI: 10.1096/fj.201802608R.


Mast Cells and Their Progenitors in Allergic Asthma.

Mendez-Enriquez E, Hallgren J Front Immunol. 2019; 10:821.

PMID: 31191511 PMC: 6548814. DOI: 10.3389/fimmu.2019.00821.


Severe refractory asthma: current treatment options and ongoing research.

Menzella F, Bertolini F, Biava M, Galeone C, Scelfo C, Caminati M Drugs Context. 2018; 7:212561.

PMID: 30534175 PMC: 6284776. DOI: 10.7573/dic.212561.


Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?.

Menzella F, Galeone C, Bertolini F, Castagnetti C, Facciolongo N J Asthma Allergy. 2017; 10:237-247.

PMID: 28919788 PMC: 5587160. DOI: 10.2147/JAA.S144100.